Tag Archives: Iressa

Afatinib Extend Time to Tumor Progression in Advanced Lung Cancer

Posted on December 22, 2010 by wngai

Currently, no treatment exists for lung cancer patients with epidermal growth-factor receptor (EGFR) mutation who have failed tyrosine kinase inhibitors, getifinib (Iressa) or erlotinib (Tarceva).  However, an investigational drug, afatinib (BIBW 2992), was recently found to increase progression-free survival and … Continue reading →

Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer | Tagged , , , , , , , , , , , , | Comments Off on Afatinib Extend Time to Tumor Progression in Advanced Lung Cancer

Gefitinib (Iressa) is better than Standard Therapy in Lung Cancer with EGFR Mutations

Posted on July 25, 2010 by wngai

Gefitinib (Iressa) is more effective than first-line therapy in improving survival without disease in patients with advanced nonsmall-cell lung cancer (NSCLC) and epidermal growth-factor receptor (EGFR) mutations.  The current study was conducted in 230 patients from 43 centers in Japan, … Continue reading →

Posted in Lung Cancer, Non Small Cell Lung Cancer | Tagged , , , , , , , , , | Comments Off on Gefitinib (Iressa) is better than Standard Therapy in Lung Cancer with EGFR Mutations

Gefitinib Improves Progression-Free Survival in Metastatic Breast Cancer

Posted on April 12, 2010 by wngai

According to a new study published in the Clinical Cancer Research, adding epidermal growth factor receptor (EGFR) inhibitor gefitinib (Iressa) to anastrozole (Arimidex) improved progression-free survival in postmenopausal women with hormone receptor-positive metastatic breast cancer. The study randomized 93 postmenopausal … Continue reading →

Posted in Breast cancer, Cancer | Tagged , , , , , | Comments Off on Gefitinib Improves Progression-Free Survival in Metastatic Breast Cancer